Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence
of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and …

Antiphospholipid syndrome is an autoimmune disorder characterized by vascular
thrombosis and/or pregnancy morbidity associated with persistent antiphospholipid antibody …

Objective Coagulopathy is one of the characteristics observed in critically ill patients with
coronavirus disease 2019 (COVID‐19). Antiphospholipid antibodies (aPLs) contribute to …

Objective To analyze the clinical and immunologic manifestations of patients with
catastrophic antiphospholipid syndrome (CAPS) from the “CAPS Registry”. Methods The …

First described in the early 1980s, antiphospholipid syndrome (APS) is a unique form of
acquired autoimmune thrombophilia in which patients present with clinical features of …

Objective Antiphospholipid syndrome (APS) is a leading acquired cause of thrombotic
events. Although antiphospholipid antibodies have been shown to promote thrombosis in …

Potentiation of neutrophil extracellular trap (NET) release is one mechanism by which
antiphospholipid antibodies (aPL Abs) effect thrombotic events in patients with …

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by
arterial and venous thrombotic manifestations and/or pregnancy-related complications in …

Connective tissue diseases (CTDs) such as systemic lupus erythematosus, systemic
sclerosis, myositis, Sjögren's syndrome, and rheumatoid arthritis are systemic diseases …

Objective An international multidisciplinary initiative, jointly supported by the American
College of Rheumatology and European Alliance of Associations for Rheumatology, is …